Oncopeptides AB (ONPPF)
0.265
0.00 (0.00%)
USD |
OTCM |
May 21, 16:00
Oncopeptides Cash from Operations (TTM): -30.00M for Sept. 30, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| September 30, 2023 | -30.00M |
| June 30, 2023 | -29.95M |
| March 31, 2023 | -32.64M |
| December 31, 2022 | -41.93M |
| September 30, 2022 | -85.99M |
| June 30, 2022 | -117.72M |
| March 31, 2022 | -148.81M |
| December 31, 2021 | -177.17M |
| September 30, 2021 | -159.39M |
| June 30, 2021 | -166.96M |
| March 31, 2021 | -155.27M |
| December 31, 2020 | -141.62M |
| Date | Value |
|---|---|
| September 30, 2020 | -129.81M |
| June 30, 2020 | -106.88M |
| March 31, 2020 | -90.05M |
| December 31, 2019 | -73.11M |
| September 30, 2019 | -62.72M |
| June 30, 2019 | -51.51M |
| March 31, 2019 | -49.04M |
| December 31, 2018 | -38.45M |
| September 30, 2018 | -29.21M |
| June 30, 2018 | -31.09M |
| March 31, 2018 | -29.28M |
| December 31, 2017 | -31.86M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-177.17M
Minimum
Dec 2021
-29.95M
Maximum
Jun 2023
-100.08M
Average
-98.46M
Median
Cash from Operations (TTM) Benchmarks
| Abliva AB | -0.7369M |
| Karolinska Development AB | -2.114M |
| Calliditas Therapeutics AB | -- |
| Olink Holding AB | -42.12M |
| BioInvent International AB | -31.06M |